Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-10 9:30 pm Purchase |
2025-02-03 | 13D | Metsera, Inc. MTSR |
ARCH Venture Fund XII, L.P. | 26,829,220 25.500% |
26,829,220 (New Position) |
Filing History |
| 2024-11-22 5:33 pm Purchase |
2024-11-12 | 13D | Neumora Therapeutics, Inc. Common Stock NMRA |
ARCH Venture Fund XII, L.P. | 31,979,111 19.800% |
12,904 (+0.04%) |
Filing History |
| 2024-11-22 5:32 pm Purchase |
2024-11-12 | 13D | Prime Medicine, Inc. PRME |
ARCH Venture Fund XII, L.P. | 15,511,736 11.800% |
39,062 (+0.25%) |
Filing History |
| 2024-11-14 5:13 pm Purchase |
2024-09-30 | 13G | Rapport Therapeutics, Inc. Common Stock RAPP |
ARCH Venture Fund XII, L.P. | 3,728,738 10.200% |
3,728,738 (New Position) |
Filing History |
| 2024-02-22 9:31 pm Purchase |
2024-02-15 | 13D | Prime Medicine, Inc. PRME |
ARCH Venture Fund XII, L.P. | 15,472,674 12.900% |
15,472,674 (New Position) |
Filing History |
| 2023-12-15 5:06 pm Purchase |
2023-12-08 | 13D | Neumora Therapeutics, Inc. Common Stock NMRA |
ARCH Venture Fund XII, L.P. | 31,966,207 20.900% |
2,168,831 (+7.28%) |
Filing History |
| 2023-09-29 8:22 pm Purchase |
2023-09-19 | 13D | Neumora Therapeutics, Inc. Common Stock NMRA |
ARCH Venture Fund XII, L.P. | 29,797,376 19.600% |
29,797,376 (New Position) |
Filing History |